In the context of breast cancer, GRHL2 induces an epithelial phenotype in mammary cells and its expression prevents tumour initiation in breast cancer xenografts, sensitises breast cancer cells to chemotherapy, and suppresses the emergence of treatment-resistant cancer stem cells [146]. Here, GRHL2 is linked to neoplasm.